

# Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/I354597BEAF2EN.html>

Date: January 2020

Pages: 127

Price: US\$ 3,500.00 (Single User License)

ID: I354597BEAF2EN

## Abstracts

Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020

### SUMMARY

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 40 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 7, 1, 17 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Metastatic Melanoma, Bladder Cancer, Glioblastoma Multiforme (GBM), Colorectal Cancer, Lung Cancer, Recurrent Glioblastoma Multiforme (GBM), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Alopecia, Breast Cancer, Cervical Cancer, Colon Cancer, Colon Carcinoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer,

Hematological Tumor, High-Grade Glioma, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medulloblastoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Traumatic Brain Injury, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer and Urethral Cancer.

The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects

The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development

BeiGene Ltd

BirchBioMed Inc

Bristol-Myers Squibb Co

CanBas Co Ltd

Eli Lilly and Co

Emcure Pharmaceuticals Ltd

F. Hoffmann-La Roche Ltd

Guangzhou BeBetter Medicine Technology Co Ltd

Hutchison MediPharma Ltd

Incyte Corp

IO Biotech ApS

Jiangsu Hengrui Medicine Co Ltd

Kyowa Kirin Co Ltd

Luye Pharma Group Ltd

Merck & Co Inc

Nammi Therapeutics Inc

Netherlands Translational Research Center BV

NewLink Genetics Corp

Orpheris Inc

Phenex Pharmaceuticals AG

Regen BioPharma Inc

Secarna Pharmaceuticals GmbH & Co. KG

Shanghai De Novo Pharmatech Co Ltd

SignalRx Pharmaceuticals Inc

Suzhou Kintor Pharmaceutical Inc

Syntekabio Inc

Tara Immuno-Oncology Therapeutics LLC

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Drug Profiles

(IO-102 + IO-103) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AI-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Dormant Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Discontinued Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Product Development Milestones

Featured News & Press Releases

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1)  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by BeiGene Ltd, H1 2020  
Pipeline by BirchBioMed Inc, H1 2020  
Pipeline by Bristol-Myers Squibb Co, H1 2020  
Pipeline by CanBas Co Ltd, H1 2020  
Pipeline by Eli Lilly and Co, H1 2020  
Pipeline by Emcure Pharmaceuticals Ltd, H1 2020  
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020  
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H1 2020  
Pipeline by Hutchison MediPharma Ltd, H1 2020  
Pipeline by Incyte Corp, H1 2020  
Pipeline by IO Biotech ApS, H1 2020  
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020  
Pipeline by Kyowa Kirin Co Ltd, H1 2020  
Pipeline by Luye Pharma Group Ltd, H1 2020  
Pipeline by Merck & Co Inc, H1 2020  
Pipeline by Nammi Therapeutics Inc, H1 2020  
Pipeline by Netherlands Translational Research Center BV, H1 2020  
Pipeline by NewLink Genetics Corp, H1 2020

Pipeline by Orpheris Inc, H1 2020  
Pipeline by Phenex Pharmaceuticals AG, H1 2020  
Pipeline by Regen BioPharma Inc, H1 2020  
Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020  
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020  
Pipeline by SignalRx Pharmaceuticals Inc, H1 2020  
Pipeline by Suzhou Kintor Pharmaceutical Inc, H1 2020  
Pipeline by Syntekabio Inc, H1 2020  
Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020  
Discontinued Products, H1 2020  
Discontinued Products, H1 2020 (Contd..1), H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Top 10 Indications, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

BeiGene Ltd  
BirchBioMed Inc  
Bristol-Myers Squibb Co  
CanBas Co Ltd  
Eli Lilly and Co  
Emcure Pharmaceuticals Ltd  
F. Hoffmann-La Roche Ltd  
Guangzhou BeBetter Medicine Technology Co Ltd  
Hutchison MediPharma Ltd  
Incyte Corp  
IO Biotech ApS  
Jiangsu Hengrui Medicine Co Ltd  
Kyowa Kirin Co Ltd  
Luye Pharma Group Ltd  
Merck & Co Inc  
Nammi Therapeutics Inc  
Netherlands Translational Research Center BV  
NewLink Genetics Corp  
Orpheris Inc  
Phenex Pharmaceuticals AG  
Regen BioPharma Inc  
Secarna Pharmaceuticals GmbH & Co. KG  
Shanghai De Novo Pharmatech Co Ltd

SignalRx Pharmaceuticals Inc  
Suzhou Kintor Pharmaceutical Inc  
Syntekabio Inc  
Tara Immuno-Oncology Therapeutics LLC

## I would like to order

Product name: Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/I354597BEAF2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I354597BEAF2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970